First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal
- Written by PR Newswire
![]() |
HONG KONG, Aug. 26, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1/CTLA-4 bi-specific antibody developed by...















